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The programming of CIs is essential for good performance. However, no Good Clinical Practice guidelines exist.This paper reports
on the results of an inventory of the current practice worldwide. A questionnaire was distributed to 47 CI centers.They follow 47600
recipients in 17 countries and 5 continents.The results were discussed during a debate. Sixty-two percent of the results were verified
through individual interviews during the following months. Most centers (72%) participated in a cross-sectional study logging
5 consecutive fitting sessions in 5 different recipients. Data indicate that general practice starts with a single switch-on session,
followed by three monthly sessions, three quarterly sessions, and then annual sessions, all containing one hour of programming
and testing.Themain focus lies on setting maximum and, to a lesser extent, minimum current levels per electrode.These levels are
often determined on a few electrodes and then extrapolated.They aremainly based on subjective loudness perception by the CI user
and, to a lesser extent, on pure tone and speech audiometry. Objective measures play a small role as indication of the global MAP
profile. Other MAP parameters are rarely modified. Measurable targets are only defined for pure tone audiometry. Huge variation
exists between centers on all aspects of the fitting practice.
1. Introduction
Cochlear implants (CI) processors must be appropriately
programmed and customized for the recipient [1, 2]. The aim
of this is to set a number of parameters to ensure that the elec-
trical pattern generated by the device in response to sound
yields optimal speech intelligibility. Several electrical para-
meters are available and all their values together is commonly
called the MAP. Finding and programming the optimal
values for a recipient is commonly called the act of fitting. It is
achieved using proprietary software and a hardware interface
connected to the processor and depends on behavioral
responses from the CI recipient.
After the initial switch-on or activation of the processor,
several fitting sessions are normally required [3]. Most of the
MAP adjustments take place over these first fewmonths, until
levels remain relatively stable [3–5]. Following stabilization of
electrical dynamic range, fitting sessions are usually limited
to periodical checks, typically annually, as long as progress
remains satisfactory.
Training in fitting is usually provided primarily by the CI
manufacturers, and, although there are guidelines and rec-
ommendations, no standardized methodology exists. There
are no agreed standards or targets for what should be adjusted
or the outcomes expected; as a consequence the MAP a
recipient receives could be very different depending on the
center visited and the individual heuristics of the audiologist
responsible. Most implant teams have an expert opinion of
what the expected level of performance for an individual
recipient should be and more detailed adjustments are made
to the MAP if this target is not reached.
This paper attempts to describe the current state of the
art by providing a comprehensive inventory of the fitting
strategies in a substantial number of CI centers worldwide.
It is beyond the scope of this paper to explain the meaning of
all possibleMAPparameters or settings. For this information,
the reader is referred to the companies’ user manuals and to
existing comprehensive overviews [2, 6].
2. Material and Methods
In preparation for an international debate which was orga-
nized in Antwerp, Belgium, in October 2012, a questionnaire
was distributed to 47 CI centers worldwide. All question-
naires were returned. All responses were analyzed and the
data were discussed during the two-day debate. After this
debate all centers were invited to a remote interview (tele-
phone or Skype) to clarify and correct the answers where
needed. In addition, the participating centers were invited
to log one single fitting session in 5 consecutive recipients
of one same CI brand in the months of September-October
2012. This yielded a prospective cross-sectional snapshot of
the actual fitting procedure which served as verification for
the questionnaire statistics.
The questionnaire is available online (see Suppleme-
ntary Material available online at http://dx.doi.org/10.1155/
2014/501738). Briefly the questions focused on the following
topics:
(i) number of implant recipients being followed and the
annual increase,
(ii) brands of implants being implanted and fitted,
(iii) MAP parameters being modified from default at
switch-on and during the followup,
(iv) assessments undertaken (subjective, objective, and
psychoacoustic) and used to steer the MAP modifi-
cations,
(v) well defined targets used.
The cross-sectional log files contained for each subject the
actual values of the different MAP parameters and whether
they had been modified during the session under study. In
addition, they also contained the information on whether
or not objective or psychoacoustic measures were executed
during the session.
We summarized all answers either numerically (counts,
percentages) or categorically (e.g., the categories: never, exce-
ptionally, sometimes, regularly, and always). In addition, all
supplementary information, nuances, and specificationswere
recorded when relevant.
Descriptive statistics were used and the results are pre-
sented graphically by means of histograms or box and
whisker plots. Distributions are described by medians, quar-
tile ranges (QR: between 25th and 75th percentile), extremes
(minimum and maximum), and outliers.
The term Cochlear is used for the Nucleus device
(Cochlear Corporation, Sydney Australia), Med-El for the
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Med-El device (Med-El, Innsbruck Austria), AB for the
Advanced Bionics device (Advanced Bionics Corporation,
Valencia, California), and Neurelec for the Digisonic device
(Neurelec, Vallauris, France). Throughout the text, the term
minimum level is used for the T, THR, T, or MIN parameters
of Cochlear, Med-El, AB, and Neurelec, respectively. The
term maximum level is used for the C, MCL, M, or MAX
parameters. In this paper the term eCAP (electrically evoked
compound action potential) is interchangeable with eCAP
threshold measurements and refers to (t)NRT, (t)ART, and
(t)NRI for Cochlear, Med-El, and AB, respectively.
3. Results
3.1. Participating Centers. Forty-seven centers from 17 differ-
ent countries (Australia, Belgium, Canada, France, Germany,
India, Italy, Lebanon, Morocco, Norway, Poland, Romania,
Spain, The Netherlands, Turkey, United Kingdom, and USA)
and 5 different continents (Europe with 60% of centers,
North-America 11%, Asia 4%, Australia 4%, and Africa 2%)
filled out the paper survey (see full list at the end of the
paper). All together they were following 47600 CI users
with an annual increase of 4800. Twenty-nine centers had a
representative being interviewed. They were following 37000
CI recipients with an annual increase of 3700.Thismeans that
the responses of 62%of the participating centers were double-
checked covering 78%of theCI recipients being followed.The
cross-sectional snapshot yielded data from255 fitting sessions
of 34 centers.
The participating centers have an average experience of 21
years (median startup in 1991; QR: 1987–2000) and a median
number of 625 implants (QR: 338–1300)with 62 new implants
last year (QR 50–123).
On average each center provides three CI brands
(Cochlear, Med-El, and AB); 10.5% provide only 1 brand;
10.5% provide 2 brands; 55% provide 3 brands, and 24%
provide 4 brands. The predominant device is Cochlear in
43% of the centers, Med-El in 29%, AB in 25%, and Neurelec
in 4%. For all three major brands we received responses
from at least 26 centers of which at least 15 were interviewed
afterwards. Only Neurelec was underrepresented, with 4
centers responding on paper of which 3were interviewed. For
the cross-sectional verification, at least 14 centers returned the
log files of 5 consecutive CI users for each of themajor brands.
For Neurelec 7 centers returned the log files.
79.5% of centers in the study provide implants to both
children and adults, 17% to adults only, and 3.5% to children
only.
3.2. Switch-On Procedures. On average, the CI processor is
switched on after 28 days (QR: 21–30) with some centers
starting after 2 weeks (Perth, Melbourne, and Chapel Hill)
while one center only hooks up the processor after 6 weeks
(Cambridge).
All centers (100%) start with impedance measurements
and if short or open most of them (60%) deactivate the cor-
responding electrodes immediately. Two centers (Brus-
sels, Freiburg since 2013) systematically execute pure tone
audiometry prior to switch-on to assess possible residual
hearing, while another centre (Hannover) does this during
the switch-on week (see further).
Most, if not all, centers’ focus goes to the setting of the
minimum and the maximum current level of the electrodes.
Med-El has a default THR level of 0 and 70% of centers do not
change this. AB recommends setting the T level at 10% of the
M level and 22% of centers do so. Amajority of centers (55%)
only determine either the minimum (31%) or the maximum
(24%) level and make the other level depend on the first one.
Forty-five percent of centers determine both the minimum
and the maximum level behaviorally.
3.2.1. DetermineMinimum Level Alone. If only theminimum
level is determined, this is either done behaviorally (56%) or
by means of intraoperative or postoperative eCAP thresholds
(44%).The eCAPmeasures aremostly followed by behavioral
verification and adjustment if necessary. Most centers (78%)
only determine the minimum levels on a few electrodes
and interpolate the values obtained to the other electrodes.
Maximum levels are then positioned at one or more intervals
above the minimum levels and most centers (67%) perform
some form of loudness balancing before switching on the
microphone. One centre (Leiden) uses a preset profile of
maximum levels which is positioned above the determined
minimum levels.
3.2.2. Determine Maximum Level Alone. Determining only
the maximum level is restricted to Med-El and AB implants
where the minimum level is then set at 0 or 10% of the
maximum level. The maximum level is either determined
behaviorally (71%) or by means of objective measures (eCAP
in 29%, which is combined with or replaced by ESRT
(electrically evoked stapedius reflex thresholds) in 14%). If
objective measures are used, behavioral verification is done
by half of the centers. Interpolation is used in only a minority
of centers (29%) and so is loudness balancing (43%).
3.2.3. Determine Both Minimum and Maximum Level. Many
centers determine both the minimum and the maximum
levels and they all do this behaviorally. Only 15% of these
combine this with eCAP measures. One center (Antwerp)
has a particular way of using preset MAPs with minimum
and maximum levels based on statistical analysis of MAPs
which have provided good results in other recipients [7, 8].
These preset MAPs are given without any prior behavioral or
other evaluation. Most centers (69%) measure the levels on a
number of electrodes and interpolate the levels on the other
electrodes. In some cases this can be as few as 3 electrodes
(Southampton, Iasi), the results of which are then used to shift
a preset profile towards the measured levels. Most centers
perform some kind of loudness balancing (62%).
In general, if the maximum levels are measured rather
than being derived from the minimum levels, half of the
centers (50%) reduce these levels before switching on the
microphone. Just after switching to live mode, almost all
centers (93%) increase or decrease themaximum levels based
on the recipient’s perception and some (45%) also shift the
minimum levels. A small number of centers perform some
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kind of psychoacoustic test immediately after switch-on, for
example, filtered Ling sounds loudness scaling (Nijmegen),
Ling sounds detection (Perth), or closed or open set word
understanding (Paris, Chapel Hill).
Most centers (76%) send the CI user home with incre-
mental MAPS after the switch-on session. These MAPS con-
tain progressively higher maximum levels allowing the CI
user to accommodate to each MAP before switching to the
next one. Some centers (17%) set a large volume range and
instruct the CI recipient to increase the volume progressively
over time. One center (Hannover) replied that they do not
systematically increase the maximum level over time.
3.2.4. Other MAP Parameters. Figure 1(a) shows that other
MAP parameters are rarely modified from default during the
switch-on session.
Cochlear. Thirteen percent of centers prefer more than the
default 8 Maxima (9, 12 or 14) and 6% combine this with a
higher than default Channel Rate (1200 pps). The Autosensi-
tivity function is switched off by 13% of centers at switch-on.
The Eargroup in Antwerp sets different Gains (statistically
defined profile), and Analysis T-SPL (20), Analysis C-SPL
(70) and switches off the ADRO function. The latter is also
done by Nottingham where T-SPL is set to 25 dB and C-SPL
is set to 75 dB at switch-on, in combination with a Q-factor
of 16; both ADRO and ASC are deactivated. Paris also sets
the Loudness Growth Function (Q-factor) at 16. The Volume
Adjustment is set to 0 by 10% of centers, all located in the
UK.
Med-El. With the Med-El device, 23% of centers start with a
different strategy than the default FS4 strategy. Chapel Hill
provides the patients with two strategies, HDCIS or FSP,
which are the two strategies approved for use in the USA.
Perth lets the patients chose between FS4 and FS4p and
has experienced that 90% of recipients prefer FS4p. Paris-
Avicenne gives FS4p as startup strategy and York, Paris-
Beaujon, and Kansas City give FSP as start-up strategy. The
lowest filter frequency is set to 70Hz by 23% of the centers.
Paris-Avicenne overrules the default settings for Highest
Frequency (set to 8000Hz), AGC Sensitivity (set to 85%),
and MapLaw (set to 1000), Nottingham overrules the default
MinimumPulseWidthDuration (set to 20𝜇s), andNijmegen
uses a high MapLaw setting (1000).
Advanced Bionics. With the AB device a majority of centers
overrule the default strategy (HiRes-P) and start with the
HiRes-S strategy (72%), and of those, two-thirds select the
Fidelity 120 strategy compared to one-third who stay with
the default setting with Fidelity 120 switched off. This is in
contrast to the centers who keep the HiRes-P strategy, of
which 78% also keep the default setting with Fidelity 120 off.
Some centers (20%) switch on Clearvoice systematically and
some centers (30%) change the default Pulse Width setting
of 10.8 𝜇sec to either a higher value or to the automatic Pulse
Width algorithm II (APW2).Thedefault input dynamic range
(IDR = 60 dB) is changed by 24% of centers. Some lower
it to 50 dB (Las Palmas, Paris-Avicenne) or 54 dB (Naples)
while others increase it to 70 dB (London St-Thomas, Beirut,
and Kerala) or to 80 dB (Antwerp). Antwerp also sets the
sensitivity to −10 dB and the Gains to a preset profile which
differs from the default values (0 dB).
Neurelec. The statistics of Neurelec’s Digisonic device are
not solid since they are derived from merely four centers,
one of which (Southampton) only uses the binaural version.
Half of them change the default number of maxima from
12 to 11 (Antwerp) or 6, depending on the duration of dea-
fness (Southampton), and one center (Antwerp) switches the
stimulation rate systematically from 600 pps to 500 pps and
the preemphasis (e´galisation de sonie) to −1.
3.2.5. Time. Figure 2 shows that 71% of the centers consider
the switch-on as 1 single session. Eleven percent spread the
switch-on over 4 sessions or more, often on consecutive
days. One center organizes the switch-on over 7 sessions
(Oslo). The median cumulative time spent is 1 hour. This
does not take into consideration the time spent for counseling
or instructing the patient. As said earlier, testing is rarely
undertaken during the switch-on session. There are outliers
who spend more than 3 hours on fitting (Coimbra, London
St-Thomas, Freiburg, Southampton, Kiel, and Oslo) or more
than 1 hour at testing (Oslo, Montpellier, and Kiel). One
center reports spending no more than 5 minutes in total,
which is the result of a fully automated switch-on (Antwerp).
There are no statistically significant differences between
centers who perform cochlear implantations mainly in chil-
dren compared to mainly in adults (Mann-Whitney 𝑈 test
𝑃 > 0.05).
3.3. Followup Procedures. After the switch-on session, all
centers schedule a number of consecutive sessions to reach
stable MAP settings. The average center schedules 3 sessions
in the first quarter, 3 sessions in the following 3 quarters,
and 1 annual session thereafter (see further). Attention goes
mostly to the verification and adjustments of minimum
and/or maximum levels to optimize loudness and almost half
of the centers (46%) explicitly say that the followup sessions
are roughly the same as the switch-on session.
3.3.1. Adjustment of Minimum and Maximum Levels. All
centers adjust maximum levels and many of them (61%)
also adjust minimum levels. Global shifting of the maximum
profile is very common (96%) while tilting is done by less
than half of the centers (39%). One centre lets the CI-
user set and balance his/her own maximum level to most
comfortable (Grenoble). All centers perform some kind of
loudness balancing across individual electrodes and some
centers perform pitch ranking (17%).
Psychoacoustical tests (tonal audiometry, speech audio-
metry) or objective measures (eCAP, ESRT) are commonly
performed (see below). Fourteen percent of the centers report
using these early stage sessions to try out different strategies
or different settings ofMAP parameters other thanminimum
and maximum levels.
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Figure 1: Occurrence of MAP changes for the 4 brands (Cochlear, Med-El, AB, and Neurelec). (a) The left panel shows the frequency of
changing the default settings at switch-on, as retrieved from the questionnaire and the interview; (b) the mid panel shows the distribution of
the frequencies of changing the MAP parameters during the followup sessions, as retrieved from the questionnaire and the interview (Box
and Whisker plots with the central dot depicting the median value, the box shows the quartile range and the whiskers show the range); (c)
the right panel shows the occurrence of MAP changes as observed in the cross sectional snapshot.
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Figure 2: Time analysis of the switch-on session, showing the number of sessions at daily intervals which are considered to constitute the
switch-on procedure (pie chart at the left) and the time spent at the switch-on session (box and whisker plot at the right), both the total time
and its breakdown into time spent at fitting and at testing. Time for counseling has not been enquired in this study. See caption of Figure 1 to
interpret the box and whisker plots.
3.3.2. Adjusting Other MAP Parameters. Figure 1(b) shows
that MAP parameters other than minimum and maximum
levels are rarely modified. This is further illustrated by
Figure 1(c) showing the cross-sectional observations. Deac-
tivation of electrodes is one of the more common actions,
but centers still report to doing this only every now and
then (median response value is between exceptionally and
sometimes, corresponding to approximately 10–15% in the
cross-sectional data). Figure 3 shows the reasons reported
to deactivate electrodes. The most commonly reported rea-
son is abnormal impedances, which is reported to occur
“sometimes”. Electrodes are also deactivated for other reasons
such as when there is an indication of extracochlear loca-
tion, if they cause nonauditory stimulation, uncomfortable
perception or if they are inaudible, if the maximum levels
are exceptionally high, or if tonotopical tests such as pitch
ranking, channel separation, or spectral discrimination show
unexpected results. These situations are reported to occur
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Figure 3: Alleged reasons for deactivating electrodes and the
frequency they are reported to be really responsible for electrode
deactivation in daily live.
almost never. Electrodes are hardly ever deactivated based
on loudness assessment or objective measures. Other excep-
tional reasons of electrode deactivation are negative results
on an integrity tests or the desire to increase the stimulation
rate. One centre used to systematically start with one or more
deactivated electrodes (Leiden) [9], a practice which has only
recently been abandoned.
Cochlear. With the Cochlear device, the additional MAP
parameter which is modified most, though still only excep-
tionally, is the Autosensitivity feature, which is then deacti-
vated. In the cross-sectional data, also channel rate, number
of maxima, and pulse width were modified in 5–8% of cases.
Med-El. With the Med-El device, the strategy is reported
to be changed in “some” cases. Some centers change the
default strategy (FS4 except in the USA) to FSP or FS4p
in exceptional or some cases. One centre routinely sets the
strategy to HDCIS in the primary program (Chapel Hill) and
lets the patient choose between this strategy and FSP. This
was confirmed in the cross-sectional data, which also showed
that AGC Sensitivity, MinimumDuration, andMapLawwere
changed in 11–14%of the cases and bymany centers (36–79%).
Advanced Bionics. Advanced Bionics has more MAP param-
eters modified by a substantial number of centers in the
course of the early followup period. The Clearvoice feature
is activated sometimes to regularly (14% of cases in the cross-
sectional study and 36% of the centers), and also the Fidelity
120 feature is sometimes changed. Pulse width and IDR are
next in line, but they are only changed in exceptional cases.
This is confirmed by the cross-sectional data where these
MAP parameters were only changed in 4–7% of the cases and
by less than 25% of the centers. In the cross-sectional data the
pulse rate was more often changed (IPI delay, 13% of cases,
and 29% of centers).
Neurelec. Neurelec again has too few data to allow any
reliable statements. The results are nevertheless included in
the graphs for completeness.
3.3.3. Time. Figure 4 shows that most centers schedule
between 5 and 8 additional sessions during the first year
(median = 6; QR: 5–8, range: 3–15). The median cumulative
time spent at the acts of fitting and testing during the first year
after switch-on is 6 hours (median for fitting = 3.3 hours and
for testing = 2.0 hours). There are no significant differences
between centers who perform cochlear implantations mainly
in children compared to mainly in adults (Mann-Whitney 𝑈
test 𝑃 > 0.05).
After the first year, the median number of sessions per
year is 1 (QR: 1-1, range 0.3–1 with one outlier with 3 annual
sessions). The median time spent is 1.3 hours (QR: 0.9–2.0
hours, range 0.5–4 hours with one outlier of 8 hours per year)
of which 0.5 hour for fitting and 0.8 hour for testing.
3.4. Outcome Measurements. Figure 5 shows that most cen-
ters report assessing subjective features and using them for
fitting. Overall comfort (93%), auditory comfort (83%), and
the presence of nonauditory sensations (83%) are used by
most centers. None of the centers reports well defined and
measurable targets for any of these features. Non auditory
satisfaction, such as contentment, quality of life, implant use,
are commonly assessed (87%) but only used by 41% of the
centers to change the MAP settings.
Of the objective measures [10], electrode impedances are
measured by 100% and used by 85% of the centers. They are
used to deactivate electrodes in case of short or open circuit.
Thresholds based on eCAP [11] or eSRT [12] measurements
are used by 59% and 39% of the centers, respectively. They
are mainly used to set the MAP profiles. Medical imaging is
used by 46% of the centers to change the fitting, mainly to
deactivate electrodes which are believed to be extracochlear.
Other objective measures may be performed, but they are not
used to drive the fitting. None of the centers report using
objective measures to reach well defined targets during the
fitting, except for Nottingham, where ESRT measures are
used for loudness balancing of theMAPs.The cross-sectional
data confirmed that, besides impedance measurements, no
objective measure was performed in more than 5% of the
cases.
Psychoacoustic measures are the only outcome measures
for which a number of centers have well defined targets. This
holds mainly for pure tone audiometry (85%) with targets
set between 20 and 40 dBHL (median 30 dBHL, QR: 25–
35 dBHL; see Figure 6). Spectral discrimination tests are used
to drive the fitting by 41% of the centers of which 20%
use well defined targets (either 100% if the A§E phoneme
discrimination test [13] is used or 83–100% if Ling sounds are
used). Speech audiometry in quiet or in noise are reported
to be used to change the MAP parameters by 61% and 41%,
respectively, but only 11% of the centers have set well defined
targets and this is only for speech audiometry in quiet. No two
centers have set the same target for this measure; however,
acoustical loudness scaling is used to change the fitting by
24%, but only 8% have well defined targets, which are the
same across centers, namely, results falling in the normal zone
(of hearing listeners).
The cross-sectional data confirm that free field audiom-
etry was performed in 60% of the cases, speech audiometry
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Figure 4: Time analysis of the follow-on sessions during the first year after switch-on, showing the number of sessions (pie chart at the left)
and the cumulative time spent at them (box and whisker plots at the right), both the total time and its breakdown into time spent at fitting
and at testing. Time for counseling has not been enquired in this study. See caption of Figure 1 to interpret the box and whisker plots.
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Figure 5: It shows the different outcome assessments which were
enquired in the questionnaire together with the frequencies of the
responses. The outcomes are grouped into 3 groups (subjective,
objective, and psychoacoustic outcomes).The possible answers were
(1) yes we assess this and use it to optimize the fitting (solid black and
grey bars), (2) yes we assess this but for other reasons than steering
the fitting, like for documentation or longitudinal followup (shaded
bars), or (3) no we do not use to assess this (white bars). For the
solid bars (assess and use it) a distinction was made into whether
they have well defined targets to reach (black) or not (grey).
was performed in quiet in 45%of cases, speech audiometry
was performed in noise in 19% of cases, loudness scaling was
performed in 11% of cases, and spectral discrimination tests
were performed in 15% of the cases. Other tests used were
speech tracking and Ling sounds detection, discrimination
and loudness scaling tests, but these were very rare.
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Figure 6: Histogram showing the frequency of the reported audio-
metric targets (dBHL) at different centers.
4. Discussion
Multichannel intracochlear implants have been clinically
available for more than 25 years. The fitting of the processors
to the individual recipient is considered to be crucial in
obtaining good results. To date there is neither well described
and commonly adopted Good Clinical Practice (GCP) for
this act nor evidence based material to distinguish efficient
procedures from less efficient ones. Over these 25 years,
fitting a CI has been carried out by competent clinicians
who have established their own heuristics, good practices,
and empirical knowledge. It seems reasonable to believe
that a critical analysis of the cumulative knowledge acquired
over the years may serve as a first step towards a definition
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of GCP. This report attempts to give an inventory of the
current state of the art as it is based on a vast number of
CI centers worldwide. All together they represent over 47000
CI recipients and 93% of the participating centers have more
than 10 years of experience. 65% of the centers are European,
which may cause a bias towards an overrepresentation of
European habits. Altogether this is an unprecedented inven-
tory and we believe that it gives a representative view on the
current practices in CI fitting, which may be considered as
the benchmark of CI fitting in 2013.
It is important to consider that the conclusions are based
on a compilation of a written questionnaire, an oral interview,
and a cross-sectional fitting data snapshot. An intrinsic
weakness of such an approach is that it lacks precision. It
is based on the anamnestic summary of centers’ practices
as provided by only one representative per center, whereas
different practices may exist within one center. Yet, in the
absence of hard evidence or more accurate overall data,
an exploratory inventory like this one is a legitimate and
necessary first step towards a better understanding of the
field. The cross-sectional sample serves as verification and
substantially improves the validity of the data. We advise
the reader not to interpret the presented numerical data
as ultimately accurate but rather as indicative while always
keeping a confidence interval in mind.
A first observation is that most centers now offer 3 CI
brands and perform cochlear implantation in both children
and adults. This is different from years ago when many CI
centers only offered one brand and only performed CI in
adults.
A second observation is that, despite the huge variability
across centers (see further), some common practices can be
extracted and they would seem to be as follows.
The typical switch-on procedure takes one session com-
prising counseling and 1 hour of fitting. Testing is not
performed at this stage. The fitting procedure is as follows:
(1) connect the processor 4 weeks after surgery;
(2) measure impedances and deactivate electrodes in case
of short or open circuits;
(3) measure the maximum level behaviorally on a num-
ber of electrodes along the electrode array, and inter-
polate the others;
(4) set the minimum level at 0 for Med-El, 10% of M
for AB; for the other implants measure the minimum
level behaviorally on a few electrodes and interpolate
the others;
(5) perform loudness balancing by presenting a signal on
all electrodes successively;
(6) reduce the maximum level and switch on the micro-
phone;
(7) let the CI recipient accommodate for a few minutes
and ask whether sounds, including loud sounds,
are tolerated; increase or decrease the entire profile
of maxima in order to make loudness tolerable or
comfortable;
(8) put a number of progressive MAPs in the processor;
(9) instruct the patient to accommodate to each program
for a couple of days and switch to the next one
afterwards.
The typical first-year followupwould comprise threemonthly
sessions followed by three quarterly sessions of one hour each.
The sessions would typically look like this:
(1) perform pure tone audiometry and speech audiome-
try (in quiet);
(2) measure impedances and deactivate electrodes in case
of short or open circuits;
(3) verify the levels on individual electrodes by loudness
balancing;
(4) shift the profiles of the maximum and, if necessary,
also of the minimum levels globally;
(5) if deemed necessary, tilt themaximum levels globally;
(6) define own criteria to identify selected and excep-
tional cases in whom other MAP parameters are
modified.
We believe that the description of these typical procedures
is the common denominator of current practices and could
serve as guidelines for newcomers in the field, as the back-
bone of instructional courses, and so forth.
But, as said, it is remarkable to observe the substantial
variability across centers and this holds for virtually all
aspects of CI fitting and followup. Each CI center has its own
policy in terms of timing, content, and methodology.
The switch-on of the processor is scheduled between 2
and 6 weeks after surgery. It is obvious that concern about
wound healing is a reason not to activate the processor
too early. On the other hand one does not like to deprive
the CI recipient from audition for too long a period and it
has been shown that the natural and progressive increase
in electrode impedances after surgery is discontinued by
electrical stimulation [5, 14]. These may be factors in favor
of early device switch-on. The observation that some centers
commonly activate the processor as soon as 2 weeks after
surgery seems to suggest that 2 weeks may still be well within
the safe time window.
On average, CI recipients undergo one switch-on session
followed by six fitting sessions in the first year, each taking
approximately one hour of technical interaction (fitting and
testing) plus a considerable amount of counseling time which
has not been enquired in this survey. Behind this average
there are huge between-centers differences. Even within one
center there may be important differences between different
clinicians and between different patients (e.g., children com-
pared to adults). Most centers have one switch-on session
followed by a take-home experience for accommodation.
Some centers however schedule 5 to 7 consecutive sessions
at daily intervals (Hannover, Freiburg, and Oslo). This may
be based on the experience that such intensive schemes
lead to stable MAPS fast or it may be for practical reasons,
for instance, for patients who are living at a distance from
the CI center. In some cases this is compensated by fewer
followup sessions in the first year, as in Hannover and Oslo,
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where no more than 4 followup sessions are scheduled in
the year after switch-on, but not in Freiburg, where 10 more
sessions are planned in the first year, a scheme which fits in a
well established rehabilitation concept. In the year following
switch-on, some centers spend no more than approximately
1.5 to 2.5 hours (Paris-Avicenne, Casablanca, Ghent, Pune,
Mumbai, Hannover, Berlin, Valencia, and Lyon) and one
center schedules only 3 sessions (Warsaw), while other
centers spend at least 12 hours (Las Palmas, Leiden, London
St-Thomas, and Amsterdam) or as much as 15 sessions
(Brussels). After the first year, there is more consistency
in terms of followup. Almost all centers have one session
per year which takes between 1 and 2 hours of technical
interaction (fitting and testing)with theCI user.Three centers
have less than 1 annual session (Hannover and London-
RNTNE every second year, Nijmegen every third year, and
Mumbai on patient’s request). It seems that these annual
sessions are merely planned for verification and to reassure
that the performance has not deteriorated, rather than for
modifying the MAPs which remain rather stable after the
initial months [15]. From that perspective it seems justified to
increase the interval of one year. However, informal feedback
from centers has revealed that these annual visits are also felt
to be important for technical checkup of the processor and
the microphone function and for ongoing counseling. When
asked about this during the above mentioned international
debate, 62% of the participants voted that annual visits were
essential during the first 5 years and this figure dropped to
28% after 5 years.
When it comes to the content of fitting and followup,
most attention goes to the setting of minimum and maxi-
mum levels per electrode. Every center appears to have its
own policy on how to determine these levels. Behavioral
assessment is commonly used, but, whereas this was per-
formed for each individual electrode in the past, it now
seems common to assess the levels on a few electrodes
only and to deduce them by interpolation for the remaining
electrodes. This probably coincides with the change from
bipolar to monopolar stimulation and is based on growing
evidence that such approach yields equally good results [16].
Evoked potentials (mainly eCAP thresholds) are used by an
important minority of the centers, but they appear to be
used as global indication of minimum or maximum levels
rather than as strict anchor points. The levels set this way
are preliminary anyhow, since they are shifted and to a
lesser extent tilted in live mode, mainly based on subjective
appreciation of loudness [17]. Whereas many reports corre-
late eCAP based MAPs with behaviorally based MAPs, as
far as we know there are no reports claiming to improve
speech understanding when eCAP based MAP optimization
is carried out. On the contrary, Smoorenburg concluded that
the applicability of eCAP measures in processor adjustment
could not be demonstrated [18]. Other MAP parameters
are rarely modified. Some default settings are systematically
overruled by a large number of centers, which probably reflect
their conviction that the default settings do not necessarily
give the best results. It seems obvious forCI companies to take
this into consideration and to change some of their default
settings. Deactivating electrodes is the most frequent next
MAP modification, although this remains rare. This may be
subject for reflection since indication exists that selectively
deactivating electrodes may substantially improve auditory
performance. When asked whether the selective dropping
of one electrode may cause a significant improvement on
speech understanding, 95% of the participants in the debate
voted affirmatively. However, it remains difficult to identify
such electrodes. The current survey demonstrates that cen-
ters have their own and often different methods to do so
(Figure 3). Finding a valid method to identify electrodes,
which, when deactivated, cause a significant improvement
in auditory performance, may be a very legitimate subject
for future research. It remains puzzling whether modifying
the many other MAP parameters is relevant or not. One
of the problems encountered is the difficulty to correctly
understand the function of these parameters and to predict
the effect of modifying them. We have developed a uniform
graphical representation for all four commercially available
implant systems to clarify this behavior in the acoustical,
electronic, and electrical domain [19] and we hope that the
interactive application which has been developed to simulate
the devices’ behavior will be instrumental for clinical use.
To the best of our knowledge, no scientific studies exist to
explore a systematic impact of modifying parameters like the
Input Dynamic Range, the Sensitivity, the AGCCompression
factor, the MapLaw, and so forth. Hence, discussing the
relevance of this can only be subject to speculation.
The most striking is the observation that the centers rely
mostly on the recipient’s subjective feedback to drive the
MAP changes. This is remarkable since many CI users have
no clear reference point to estimate the subjective quality of
sound, either because they have never had normal hearing
before or because they have been deprived of normal hearing
for many years and have got used to hearing aid sound over
the years. Also such subjective feedback is not quantitative
and can therefore hardly lead to systematic process optimiza-
tion, since this fundamentally requires measured results and
targets. In addition many experienced clinicians indicated
that patient’s subjective judgment may not coincide with
optimal performance.Objectivemeasures are only used to get
a prior estimate of the shape of the minimum or maximum
levels, but they almost never serve the fine tuning of the
device.
The expectationmight be that, after more than 25 years of
cochlear implantation, the field had developed psychoacous-
tic targets to steer the device fitting, but this survey shows
that targets only exist in terms of audiometric thresholds.One
of the reasons for this may be the fact that it is not always
obvious how to modify the MAP parameters if targets are
notmet. Current CI systems are complex and predicting their
behavior after changing theMAP is not obvious. On the other
hand, such reasoning is also vicious and defining targets may
be an incentive to explore and develop procedures to achieve
target in the most efficient ways. Most centers agree on a
target of 30 dBHL (±5 dB) for most audiometric frequencies,
and this is achievable with current microphones and front-
end processing.
Auditory performance, however, hardly depends on
thresholds but rather on supraliminal sound processing. The
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core function of the cochlea is discriminating the different
features of sound, such as loudness, spectral content, and
temporal content, and it is striking to see that less than 50%
of the centers report basing their fitting onmeasures to assess
this and that less than 25% report having targets in this
domain [13, 19]. Speech audiometry in quiet or in noise relates
to the daily auditory performance but depends on more
than just the cochlear processing of sound. Therefore speech
audiometry is only partly indicative of the quality of cochlear
functioning. Speech audiometry is used by approximately
half of the centers but most use it to monitor performance,
that is, to detect any undesired deterioration over time. Only
11% report having well defined speech audiometrical targets
when it comes to CI fitting. This is in line with instructional
literature which extensively explains the available method-
ology and how to use it to determine the minimum and
maximum levels but which avoids mentioning measurable
targets [2, 6, 20–22]. Shapiro coined the term “common
lethargy” when referring to the CI audiologists’ willingness
to consider changes in device programming and he correctly
stated that device programming is not a goal per se but the
absolute goal is to provide the patient with a comfortable
program which ensures maximum performance [2].
In conclusion, it seems fair to summarize the current
state of CI fitting as setting global profiles of maximum
current levels and to a lesser extent of minimum current
levels, mainly based on subjective feedback from the CI user.
Many different approaches exist and in the absence of targets
or well defined outcome measures it seems impossible to
compare all these differences and to judgewhether some yield
better results or are more efficient than others. It is likely
that several approaches in the hands of different experts may
lead to similarly good results. It is equally likely that defining
common measurable targets may be a next step to be taken
towards the optimization of the art of fitting.
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